What Anti-Ro (SSA), Anti-La (SSB), and Anti-Sa Antibodies Test For
Anti-Ro (SSA) and anti-La (SSB) antibodies are autoantibodies that primarily screen for Sjögren's syndrome, systemic lupus erythematosus (SLE), and identify pregnant women at risk for neonatal lupus and congenital heart block in their babies. Anti-Sa is a different antibody associated with rheumatoid arthritis, not related to Ro/La.
Primary Clinical Applications
Anti-Ro (SSA) and Anti-La (SSB)
These antibodies target specific ribonucleoprotein complexes and serve as hallmark markers for:
Sjögren's Syndrome (Primary)
- Present in 60-70% of primary Sjögren's syndrome cases 1
- Anti-SSB is more specific for Sjögren's than anti-SSA 2
- When both antibodies are positive together, they significantly increase the likelihood of Sjögren's diagnosis (53.5% show high titers) 3
- Associated with earlier disease onset, glandular dysfunction, and extraglandular manifestations 1
Systemic Lupus Erythematosus (SLE)
- Found in approximately 25% of SLE patients 4
- Particularly important: these antibodies identify the 5-10% of SLE patients who are ANA-negative on standard testing 4
- These ANA-negative, Ro-positive lupus patients typically present with prominent widespread photosensitive dermatitis 4
- Associated with prominent skin manifestations, particularly subacute cutaneous lupus 5
Pregnancy-Related Complications
- Critical screening purpose: identify risk for congenital heart block (CHB) and neonatal lupus syndrome (NLS) in offspring 5
- Guidelines recommend testing when these conditions are suspected, regardless of ANA results 5
- High anti-Ro levels (>50 U/mL) warrant weekly fetal echocardiographic screening between 16-28 weeks gestation 6
- Low anti-Ro levels (<50 U/mL) have minimal risk and targeted screening is more cost-effective than universal weekly screening 6
When to Order These Tests
The guideline explicitly states: in cases of high clinical suspicion, specific antibody testing should be performed regardless of ANA results 5. Specific indications include:
- Suspected Sjögren's syndrome (dry eyes, dry mouth, parotid enlargement)
- Suspected SLE, especially with prominent skin involvement
- Congenital heart block or neonatal lupus in offspring 5
- Subacute cutaneous lupus 5
- ANA-negative patients with clinical features suggesting autoimmune disease
Important Clinical Patterns and Pitfalls
Isolated Anti-SSB Without Anti-SSA
- Has significantly lower diagnostic utility 7
- Much less likely to be associated with Sjögren's, SLE, or rheumatoid arthritis compared to dual positivity 7
- Often represents a clinically insignificant finding 7
- Patients with isolated anti-SSB show lower rates of anemia, leukopenia, proteinuria, and positive ANA 7
Dual Positivity (Anti-SSA + Anti-SSB)
- Indicates more severe disease 7
- 64.6% present with speckled ANA pattern 3
- Higher specificity for Sjögren's syndrome 3
- Only 0.5% of dual-positive samples are ANA-negative 3
Rheumatoid Arthritis Context
- Anti-Ro/La have very low prevalence (3.9% for anti-SSA, 1.1% for anti-SSB) in RA patients 8
- Slightly higher in RF-positive RA (5.1%) versus RF-negative (1.6%) 8
- Current guidelines recommending routine testing in all RA patients wishing to conceive may need reconsideration, especially for RF-negative patients 8
Regarding "Anti-Sa"
Anti-Sa is an entirely different antibody system associated with rheumatoid arthritis, not related to Ro/SSA or La/SSB antibodies. It targets citrullinated vimentin and is part of the anti-citrullinated protein antibody (ACPA) family used in RA diagnosis.
Immunofluorescence Patterns
When positive, these antibodies typically produce:
- Fine speckled nuclear pattern (most common) 5
- Various other patterns possible, but 64.6% of dual-positive samples show speckled pattern 3
Stability Over Time
These antibodies are relatively stable once present 3. In patients followed over 2 years, anti-SSA disappeared in only 7 of 71 patients on repeat testing, and anti-SSB in 6 of 71 3. Therefore, frequent repeat testing in established Sjögren's patients is unnecessary 3.